Biodegradable Cationic Lipids for Lower-Toxicity Gene Delivery

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing cationic lipids face challenges in efficiently delivering nucleic acids into cells while minimizing liver toxicity and maintaining effectiveness.

Innovation Solution

A novel cationic lipid compound represented by formula (I) with specific alkyl and alkenyl groups, capable of forming complexes with nucleic acids, is developed, which can be combined with neutral lipids and polymers for enhanced delivery, particularly targeting genes in specific tissues like the liver, lung, kidney, digestive tract, central nervous system, or spleen, and is suitable for intravenous administration.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If existing cationic lipids are used to deliver nucleic acids into cells, then transfection efficiency is improved, but liver toxicity increases

Engineering Contradiction:
Improvetransfection efficiencyVSAvoidliver toxicity
Core Design Contradiction:
ProductivityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by introducing biodegradable groups at specific positions within the lipid molecule (in the hydrophobic region between the polar head and hydrocarbon chains) while maintaining the overall cationic lipid structure. This localized modification allows the lipid to maintain its transfection function while gaining biodegradability to reduce liver toxicity accumulation

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent creates a composite lipid structure combining non-biodegradable cationic lipid components (for transfection efficiency) with biodegradable groups (for reduced toxicity). The compound represents a hybrid material that integrates both functional requirements into a single molecular structure

Inventive Principle:
Principle #40Composite materials

2Object-affected harmful factors

If biodegradable groups are introduced to lipid chains to reduce liver toxicity, then liver toxicity is reduced, but transfection efficiency may be compromised

Engineering Contradiction:
Improveliver toxicityVSAvoidtransfection efficiency
Core Design Contradiction:
Object-affected harmful factorsVSProductivity

Solution Approach 1:

The biodegradable groups are strategically placed in the hydrophobic region of the lipid molecule, specifically in the chain region between the polar head group and the terminal hydrocarbon groups. This localized placement ensures that the biodegradability function is achieved without interfering with the critical transfection functions performed by the polar head and hydrocarbon regions

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent modifies the chemical structure by introducing specific biodegradable functional groups (such as ester bonds or other hydrolyzable linkages) that change the degradation parameter of the lipid while maintaining other critical parameters like charge density, hydrophobicity, and molecular size that are essential for transfection efficiency

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The novel compound effectively introduces nucleic acids into cells, demonstrating significant gene silencing effects through RNA interference, particularly in cancer cells, with reduced liver toxicity and improved delivery efficiency.

Implementation Method 1

forming a positively charged (total charge) complex with macromolecules such as nucleic acids

Methodology Applied
Scientific EffectElectrostatic interaction: Ion Repulsion/Attraction

Data Source

PatentEP3395797B1Compounds as cationic lipids
Publication Date: 2025.08.06 KYOWA HAKKO KIRIN CO LTD
  • EP3395797B1 patent drawingFigure 1~2
  • EP3395797B1 patent drawingFigure 3~4
  • EP3395797B1 patent drawing

AI summary

The present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as a cationic lipid, and the like.